[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"measles-mumps-rubellachickenpox-vaccine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:measles-mumps-rubellachickenpox-vaccine":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100649909","phase-3-a-study-on-the-immune-response-and-safety-of-an-investigational-combined-measles-mumps-rubella-and-varicella-vaccine-when-given-to-healthy-children-4-to-6-years-of-age-100649909",false,"NCT07742644","A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age","A Phase 3a, Observer-blind, Randomized, Controlled Study to Demonstrate Lot-to-lot Consistency and Evaluate the Immunogenicity and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine Compared With ProQuad, Administered as a Second Dose in Healthy Children 4-6 Years of Age","MMRVNS 20-002","Inclusion Criteria (INC):\n\n* INC#1 Participant's parent(s)\u002FLAR(s), who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiaries, return for follow-up visits).\n* INC#2 Written or witnessed\u002Fthumb printed or digital informed consent obtained from the participant's parent(s)\u002FLAR(s) prior to performance of any study specific procedure.\n* INC#3 Informed assent obtained from the participants in line with local rules and regulations.\n* INC#4 Healthy participants as established by medical history and clinical examination at screening.\n* INC#5 A male or female participant between and including 4 and 6 years of age (i.e., from fourth birthday until the day before the seventh birthday) at the time of the study interventions administration, and in accordance with local regulations.\n* INC#6 Participant who previously received a first dose of varicella-containing vaccine in the second year of life (i.e., from first birthday at 12 months of age until the day before the second birthday at 24 months of age).\n* INC#7 Participant who previously received a first dose of measles, mumps, rubella containing vaccine in the second year of life (i.e., from first birthday at 12 months of age until the day before the second birthday at 24 months of age).\n* INC#8 Participant who previously received 3 or 4 doses of any combined DTP (DTaP\u002FDTwP) vaccine (diphtheria and tetanus toxoids and pertussis antigens whether or not combined with hepatitis B, inactivated poliovirus or Haemophilus influenzae type b antigens) according to the local recommendations.\n\nExclusion Criteria (EXC):\n\n* EXC#1 History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions, including hypersensitivity to neomycin or gelatin.\n* EXC#2 Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).\n* EXC#3 Hypersensitivity to latex.\n* EXC#4 Unstable chronic conditions as determined by medical history and physical examination.\n* EXC#5 Major congenital defects, as assessed by the investigator.\n* EXC#6 History of measles, mumps, rubella or varicella\u002Fzoster disease as evaluated by the investigator.\n* EXC#7 History of diphtheria, tetanus, pertussis, and\u002For poliomyelitis disease.\n* EXC#8 Recurrent history or uncontrolled neurological disorders or any neuroinflammatory (including, but not limited to: demyelinating disorders, encephalitis or myelitis of any origin), congenital neurological conditions, encephalopathies, or seizures (including all subtypes, such as: absence seizures, generalized tonic-clonic seizures, partial complex seizures, partial simple seizures).\n* EXC#9 Active untreated tuberculosis.\n* EXC#10 Condition that, in the judgment of the investigator, would make intramuscular injection unsafe.\n* EXC#11 Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the clinical study.\n* EXC#12 Use of any investigational or non-registered product (drug, vaccine, or invasive medical device in the country of enrollment) other than the study interventions during the period beginning 30 days before the dose of study interventions (Day -29 to Day 1), or their planned use during the study period.\n* EXC#13 Administration of immunoglobulins or other blood products or plasma derivatives during the period starting 90 days before the study intervention or planned administration during the study period.\n* EXC#14 Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and\u002For planned use of long-acting immune modifying treatments at any time up to the end of the study.\n\n  * Up to 90 days prior to the study interventions administration.\n\n    * For corticosteroids, this will mean prednisone equivalent ≥0.5 mg\u002Fkg\u002Fday with maximum of 20 mg\u002Fday for pediatric participants. Inhaled, intra-articular\u002Fintra-bursal and topical steroids are allowed.\n  * Up to 180 days prior to study interventions administration: long-acting immune-modifying drugs including among others immunotherapy (e.g., tumor necrosis factor-inhibitors), monoclonal antibodies (except the ones not interfering with the immune response to the study interventions, e.g., nirsevimab), antitumoral medication.\n* EXC#15 Previous vaccination with a second dose of varicella-containing vaccine or measles, mumps, rubella containing vaccine.\n* EXC#16 Vaccination against diphtheria, tetanus, pertussis, and\u002For poliomyelitis given after the second year of life (i.e., after the second birthday at 24 months of age).\n* EXC#17 Occurrence of any of the following events after a previous administration of DTP vaccine:\n\n  * Encephalopathy of unknown etiology occurring during the period starting within 7 days of vaccination of a previous administration of DTP vaccine.\n  * A temperature (≥40.6°C \\[≥105°F\\]) during the period starting 48 hours after vaccination not due to another identifiable cause.\n* EXC#18 Use of salicylates (aspirin) or salicylate-containing products or its planned use, during the period of 6 weeks following study interventions administration.\n* EXC#19 Planned administration\u002Fadministration of a vaccine not foreseen by the study protocol in the period starting 30 days before the dose and ending 43 days after the dose of study interventions administration\\* (Visit 2), with the exception of\n\nInfluenza vaccines:\n\n* Inactivated influenza vaccine must not be administered in the period starting 28 days before the dose and ending 28 days after the dose of study intervention administration. If administered outside this prohibited period, it should be administered at a different location than the study intervention.\n* Live attenuated influenza vaccine must not be administered during the period starting 30 days before the dose and ending 43 days after the dose of study intervention administration (Visit 2).\n\n  * If emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is recommended and\u002For organized by public health authorities outside the routine immunization program, the time period described above can be reduced, provided it is used according to the local governmental recommendations and sponsor is notified.\n\n    * EXC#20 Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug\u002Fvaccine\u002Finvasive medical device).\n    * EXC#21 Any study personnel's immediate dependents, family, or household members.\n    * EXC#22 Child in care.\n    * EXC#23 Participants with the following high-risk individuals in their household:\n\n      * Immunocompromised individuals.\n      * Pregnant women without documented history of varicella.\n      * Newborn infants of mothers without documented history of varicella.\n      * Newborn infants born \\\u003C28 weeks of gestation.",true,"ALL","4 Years","6 Years",{"count":22,"type":23},1860,"ESTIMATED","INTERVENTIONAL",[26],"PHASE3","The purpose of this study is to evaluate how consistently 3 different manufacturing lots of the GSK's investigational measles, mumps, rubella, and varicella (MMRVNS) vaccine will produce an immune response. It will also compare the overall immune response to the MMRVNS vaccine with that of the Merck licensed measles, mumps, rubella, and varicella (MMRV) vaccine.\n\nThe vaccines will be given as a second dose to children aged 4 to 6 years who have previously received a first dose of any combination of measles, mumps, rubella, and varicella-containing vaccine(s).\n\nThe study will also assess the immune response and safety of the MMRVNS and MMRV vaccines when given at the same time as a diphtheria, tetanus, acellular pertussis, and inactivated poliovirus (DTaP-IPV) vaccine. The DTaP-IPV vaccine used is licensed as Kinrix in the United States.",[29,30,31,32,33],"Measles","Mumps","Rubella","Varicella (Chickenpox)","Measles-Mumps-Rubella+Chickenpox Vaccine",[29,30,31,32,35,36,37,38],"Combined vaccine","Immunogenicity","Vaccine safety","Children aged 4 to 6 years","NOT_YET_RECRUITING","2026-07-29",{"date":42,"type":43},"2026-08-03","ACTUAL",{"date":45,"type":23},"2026-08-11",{"date":47,"type":23},"2028-11-21",{"name":49,"class":50},"GlaxoSmithKline","INDUSTRY",62,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":17,"sex":18,"minAge":59,"maxAge":20,"enrollmentInfo":60,"targetDuration":4,"studyType":24,"phases":62,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100624186","phase-3-a-study-on-the-immune-response-and-safety-of-an-investigational-combined-measles-mumps-rubella-and-varicella-vaccine-when-administered-as-intramuscular-injection-to-healthy-children-15-months-to-6-years-of-age-100624186","NCT07406360","A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age","A Phase 3a, Observer Blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Combined Measles, Mumps, Rubella, and Varicella Vaccine Compared With Intramuscular Administration of ProQuad When Administered as a Second Dose to Healthy Children Aged 15 Months to 6 Years of Age","Inclusion Criteria:\n\n* Participants' parent(s)\u002Flegally acceptable representative(s) (LAR(s)) who, in the opinion of the investigator, can and will comply with the requirements of the protocol.\n* Written or witnessed\u002Fthumb printed informed consent obtained from the participants parent(s)\u002FLAR(s) prior to performance of any study specific procedure.\n* Informed assent obtained from the participants in line with local rules and regulations.\n* Healthy participants as established by medical history and clinical examination at screening.\n\nFor countries where the second dose of measles, mumps, rubella, and varicella vaccination is administered between 4 and 6 years of age:\n\n* A male or female participant between and including 4 and 6 years of age at the time of the study intervention administration, and in accordance with local regulations.\n* Participant who previously received a first dose of varicella-containing vaccine in the second year of life.\n* Participant who previously received a first dose of measles, mumps, rubella-containing vaccine in the second year of life.\n\nFor other countries:\n\n* A male or female participant between and including 15 months to 6 years of age at the time of study intervention administration, and in accordance with local regulations.\n* Participant who previously received a first dose of varicella-containing vaccine in the second year of life, or earlier at 11 months of age in accordance with national vaccination schedule following official recommendation, at least 3 months before study entry.\n* Participant who previously received a first dose of measles, mumps, rubella-containing vaccine in the second year of life, or earlier at 11 months of age in accordance with national vaccination schedule following official recommendation, at least 1 month before study entry.\n\nExclusion Criteria:\n\nMedical conditions\n\n* History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions, including hypersensitivity to neomycin or, gelatin.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.\n* Hypersensitivity to latex.\n* Unstable chronic conditions as determined by medical history and physical examination.\n* Major congenital defects, as assessed by the investigator.\n* History of measles, mumps, rubella, or varicella\u002Fzoster disease, as evaluated by the investigator.\n* Recurrent history or uncontrolled neurological disorders or any neuroinflammatory, congenital neurological conditions, encephalopathies, or seizures.\n* History of febrile seizures, for participant under 4 years of age.\n* Active untreated tuberculosis.\n* Condition that, in the judgement of the investigator, would make intramuscular injection unsafe.\n* Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the clinical study.\n\nPrior\u002FConcomitant therapy\n\n* Use of any investigational or non-registered product other than the study interventions during the period beginning 30 days before the dose of study intervention, or their planned use during the study period.\n* Administration of immunoglobulins or other blood products or plasma derivates during the period starting 90 days before the study intervention or planned administration during the study period.\n* Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and\u002For planned use of long-acting immune-modifying treatments at any time up to the end of the study.\n\n  * Up to 90 days prior to the study interventions administration: systemic corticosteroid.\n  * Up to 180 days prior to study intervention administration: long-acting immune-modifying drugs including among others immunotherapy, monoclonal antibodies, antitumoral medication.\n* Previous vaccination with a second dose of varicella containing vaccine or measles, mumps, rubella-containing vaccine.\n* Use of salicylates or salicylate-containing products or its planned use during the period of 6 weeks following study intervention administration.\n* Planned administration\u002Fadministration of a vaccine not foreseen by the study protocol in the period starting 30 days before the dose and ending 43 days after the dose of study intervention administration, with the exception of:\n* Inactivated influenza vaccine, which may be given at any time during the study and administered at a different location than the study intervention, and\n* Diphtheria, tetanus, acellular pertussis-containing vaccines may be administrated according to the local immunization practices of each participating country. It has to be administered on the same day as the study intervention administration at a different location. However, other than protocol-specified DTaP brand and diphtheria, tetanus, whole cell pertussis-containing vaccines are not allowed.\n\nIf emergency mass vaccination for an unforeseen public health threat is recommended and\u002For organized by public health authorities outside the routine immunization program, the time period described above can be reduced provided it is used according to the local governmental recommendations and sponsor is notified.\n\nPrior\u002FConcurrent clinical study participation\n\n• Concurrently participating in another clinical study, at any time during the study period,\n\nOther exclusion criteria\n\n* Any study personnel's immediate dependents, family, or household members.\n* Child in care.\n* Participants with the following high-risk individuals in their household:\n\n  * Immunocompromised individuals.\n  * Pregnant women without documented history of varicella.\n  * Newborn infants of mothers without documented history of varicella.\n  * Newborn infants born \\\u003C28 weeks of gestation.","15 Months",{"count":61,"type":23},1209,[26],"This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administration of the MMRV (Merck's measles, mumps, rubella and varicella) vaccine (ProQuad) that is already licensed for this route, when administered as a second dose in children 15 months to 6 years of age who were previously primed with a first dose of any combination of measles, mumps, rubella and varicella-containing vaccine(s).",[29,33],[29,30,31,66,67,36],"Varicella","Safety","RECRUITING","2026-07-07",{"date":71,"type":43},"2026-07-08",{"date":73,"type":43},"2026-05-11",{"date":75,"type":23},"2028-07-20",{"name":49,"class":50},17]